Global Markets for Treatment and Diagnosis of SexuallyTransmitted DiseasesReport Details:Published:January 2013No. of Page...
Europe, Middle East, Russia and Africa (EMRA); and Asia (Japan, China, India, Australia otherOceanic countries).SCOPE OF R...
BACTERIAL VAGINOSISCANDIDIASISCHANCROID (VENEREAL ULCERS)CHLAMYDIAGENITAL HERPESGENITAL WARTS/HUMAN PAPILLOMAVIRUSGONORRHE...
Chapter- 10: PHARMACEUTICAL TREATMENT PIPELINEEMERGING TRENDS IN DIAGNOSTIC PRODUCTSEMERGING TRENDS IN PHARMACEUTICAL PROD...
PRINCETON BIOMEDITECH CORPORATIONQIAGEN BENELUX BVQUIDELREMEL/THERMOFISHER SCIENTIFICROCHE LABORATORIES (HOFFMANN-LA ROCHE...
Table 22 : CURRENT TREATMENTS FOR GENITAL HERPESBY BRAND NAME, GENERICNAME AND MANUFACTURER, 2012Table 23 : CURRENT DIAGNO...
AMERICAS, BY DISEASE, THROUGH 2017Table 48 : ESTIMATED ANNUAL NUMBER OF PREGNANT WOMEN WITH AN STD IN THEU.S.Table 49 : AN...
Table 78 : GLAXOSMITHKLINE PHARMACEUTICAL PRODUCTSTable 79 : HOLOGIC/GEN-PROBE DIAGNOSTIC PRODUCTSTable 80 : HOME ACCESS H...
AND 2017Figure 11 : MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE, 2012 AND2017Figure 12 : MARKET FOR STD TREATMEN...
Upcoming SlideShare
Loading in …5
×

Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases

374 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
374
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases

  1. 1. Global Markets for Treatment and Diagnosis of SexuallyTransmitted DiseasesReport Details:Published:January 2013No. of Pages: 141Price: Single User License – US$5450REPORT HIGHLIGHTSThis report provides:•An overview of the markets for the diagnoses of and treatments for sexually transmitted diseases, including bacterial vaginosis, candidiasis, chancroid, chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, HIV/AIDS, pediculosis pubis, syphilis, and trichomoniasis.•Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.•Identifications of common STDs, citing risk factors, incidence, and mortality for each.•Discussion of products on the market.•A list of current and potential competitors in the market and their market shares.•Comprehensive company profiles of major players in the industry.REPORT SCOPEINTRODUCTIONREASONS FOR DOING THE STUDYThis report provides the reader with a detailed analysis of the global sexually transmitted disease(STD) diagnostic and treatment markets. It also discusses technological developments, futuretrends and emerging opportunities.The major objectives of this study are:•To assess the technology developments.•To identify the driving factors for demand.•To make available the most current and reliable information on market size.•To estimate the global supply and demand scenario broken down by disease and geographical regions.•To estimate the growth rate in demand.•To estimate the projected global supply and demand scenario over the next five years and to analyze it via application sectors as well as product types.•To identify the factors influencing this industry and make appropriate recommendations.Projections for STD diagnostic and treatment applications will be made for geographical regionsincluding the Americas (i.e., U.S., Canada, Central America [including Mexico], South America);
  2. 2. Europe, Middle East, Russia and Africa (EMRA); and Asia (Japan, China, India, Australia otherOceanic countries).SCOPE OF REPORTThis market report organizes information from diverse sources into a cohesive report that includesa disease overview, industry structure, diagnostic products, pharmaceutical products, emergingtechnology, regulations by region and patents sections.METHODOLOGY/INFORMATION SOURCESThe data for this report was gathered from primary and secondary sources. Sources includeinformation obtained from industry analysts; manufacturer and company reports; industry tradejournals; medical journals; and industry associations. Additional information was obtained throughthe U.S. Patent and Trademark Office (USPTO), U.S. Securities and Exchange Commission(SEC) filings, The World Health Organization (WHO), the Organization for Economic Cooperationand Development (OECD), the Pharmaceutical Research and Manufacturing Association,UNAIDS and Epocrates.Get your copy of this report @http://www.reportsnreports.com/reports/213312-global-markets-for-treatment-and-diagnosis-of-sexually-transmitted-diseases.htmlMajor points covered in Table of Contents of this report includeTABLE OF CONTENTSChapter- 1: INTRODUCTIONREASONS FOR DOING THE STUDYSCOPE OF REPORTMETHODOLOGY/INFORMATION SOURCESINTENDED AUDIENCEANALYST CREDENTIALSRELATED BCC REPORTSBCC ONLINE SERVICESDISCLAIMERChapter- 2: SUMMARYTable Summary : GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLYTRANSMITTED DISEASES, THROUGH 2017Figure Summary : GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLYTRANSMITTED DISEASES, 2011 AND 2017Chapter- 3: INDUSTRY OVERVIEWEPIDEMIOLOGY AND ETIOLOGY OF SEXUALLY TRANSMITTED DISEASESDIAGNOSIS OF STDVACCINESMARKET ANALYSIS BY DISEASEMERGERS AND ACQUISITIONSChapter- 4: DISEASE OVERVIEWDIAGNOSTIC TESTING
  3. 3. BACTERIAL VAGINOSISCANDIDIASISCHANCROID (VENEREAL ULCERS)CHLAMYDIAGENITAL HERPESGENITAL WARTS/HUMAN PAPILLOMAVIRUSGONORRHEAHEPATITIS B AND CHERPES SIMPLEX VIRUS (SEE GENITAL HERPES)HIV/AIDSPEDICULOSIS PUBISPELVIC INFLAMMATORY DISEASE (PID)SCABIESSYPHILISTRICHOMONIASISSTD TRENDSTable 13 : CAUSATIVE ORGANISMS FOR SEXUALLY TRANSMITTED DISEASESChapter- 5: STD DIAGNOSIS AND TREATMENT OPTIONSDIAGNOSTIC OPTIONS, BY TYPEGLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS, BY DISEASEPROJECTED GLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS, BY REGIONSTD PHARMACEUTICAL PRODUCTS, BY DISEASEGLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS, BY REGIONOPPORTUNITIES IN THE STD DIAGNOSIS AND TREATMENT MARKETChapter- 6: THE AMERICAS MARKETDIAGNOSTIC PRODUCTS IN THE AMERICASPHARMACEUTICAL TREATMENTS IN THE AMERICASANTIBIOTIC RESISTANCE IN TREATING STDSTHE U.S.CANADAChapter- 7: THE EMRA MARKETSTD DIAGNOSTIC PRODUCT MARKET IN THE EMRASTD PHARMACEUTICAL TREATMENTS IN THE EMRAANNUAL INCIDENCES OF STD DISEASE IN THE EMRAChapter- 8: THE ASIAN MARKETDIAGNOSTIC PRODUCTSSTD TREATMENT OPTIONS IN ASIAREGIONAL DISEASE PREVALENCEChapter- 9: REGULATIONSCREATING DRUG TREATMENTSREGIONAL REGULATIONS
  4. 4. Chapter- 10: PHARMACEUTICAL TREATMENT PIPELINEEMERGING TRENDS IN DIAGNOSTIC PRODUCTSEMERGING TRENDS IN PHARMACEUTICAL PRODUCTSPHARMACEUTICAL TREATMENT PRODUCT PIPELINEChapter- 11: PATENT ANALYSISPHARMACEUTICAL PATENTS ISSUED BY COMPANY, APPROVAL DATE AND DISEASEDIAGNOSTIC PATENTS ISSUED BY COMPANY, APPROVAL DATE AND DISEASEPATENTS ISSUED BY COMPANYPATENTS ISSUED BY COUNTRYPATENTS ISSUED BY DISEASEChapter- 12: COMPANY PROFILESABBOTT LABORATORIESALEREALFA SCIENTIFIC DESIGNSATLAS LINK BIOTECH CO, LTD.BAYER AGBECTON DICKINSONBIOMERIEUX, INC.BIO-RAD LABORATORIESBOEHRINGER INGELHEIM GMBHBRISTOL-MYERS SQUIBB COMPANYCREATIVE DIAGNOSTICSDIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS, INC.DIASORINENZO BIOCHEMFIRST DIAGNOSTIC LLCGENENTECH (SEE ROCHE)GEN-PROBE, INC. (SEE HOLOGIC)GILEAD SCIENCES, INC.GLAXOSMITHKLINEHOLOGIC/GEN-PROBEHOME ACCESS HEALTH, INC.IMMUNOSTICSIND DIAGNOSTIC, INC.INVERNESS MEDICAL INNOVATIONS (SEE ALERE)JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS)MERCK & COMPANY, INC.MERIDIAN BIOSCIENCENOVARTIS PHARMACEUTICAL CORPORATIONORASURE TECHNOLOGIES, INC.ORTHO CLINICAL DIAGNOSTICSPFIZER, INC.
  5. 5. PRINCETON BIOMEDITECH CORPORATIONQIAGEN BENELUX BVQUIDELREMEL/THERMOFISHER SCIENTIFICROCHE LABORATORIES (HOFFMANN-LA ROCHE INC.)SEKISUI DIAGNOSTICSSHANGHAI KEHUA BIO-ENGINEERING CO, LTD.STANDARD DIAGNOSTICS, INC.TRINITY BIOTECH PLCVERTEX PHARMACEUTICALSVIIV HEALTHCARELIST OF TABLESSummary Table : GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLYTRANSMITTED DISEASES, THROUGH 2017Table 1 : MAJOR MANUFACTURERS OF AUTOMATED STD TESTS, 2012Table 2 : MAJOR MANUFACTURERS OF RAPID AND LABORATORY DIAGNOSTIC STD KITS,2012Table 3 : MAJOR MANUFACTURERS OF VACCINES FOR STDSTable 4 : HPV DIAGNOSTIC PRODUCTS, MANUFACTURER AND MARKET SHARE, 2011Table 5 : GONORRHEA DIAGNOSTIC PRODUCT MANUFACTURERS AND PRODUCT NAMESTable 6 : MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTSTable 7 : HEPATITIS A, B AND C DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUESBY TYPE OF TEST, 2011Table 8 : MARKET STANDING OF MAJOR HEPATITIS B AND C TREATMENTMANUFACTURERS BY REVENUES, 2011Table 9 : HIV DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE, 2011Table 10 : HIV/AIDS TREATMENT MANUFACTURER MARKET STANDING BY REVENUES,2011Table 11 : NUMBER OF DIAGNOSTIC AND PHARMACEUTICAL MANUFACTURERS, BYDISEASE TREATED, WITH REVENUES AND MARKET SHARE, 2011Table 12 : SELECTED MERGERS AND ACQUISITIONS, 2008-2012Table 13 : CAUSATIVE ORGANISMS FOR SEXUALLY TRANSMITTED DISEASESTable 14 : CURRENT DIAGNOSTIC TESTS FOR BACTERIAL VAGINITISTable 15 : CURRENT TREATMENTS FOR BACTERIAL VAGINITISTable 16 : DIAGNOSTIC TESTS FOR CANDIDIASISTable 17 : TREATMENTS FOR VULVOVAGINAL CANDIDIASISTable 18 : CURRENT MEDICATIONS USED TO TREAT CHANCROID ULCERSTable 19 : CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE ANDMANUFACTURER, 2012Table 20 : CURRENT MEDICATIONS USED TO TREAT CHLAMYDIATable 21 : CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPESBYBRAND NAME, TYPE AND MANUFACTURER, 2012
  6. 6. Table 22 : CURRENT TREATMENTS FOR GENITAL HERPESBY BRAND NAME, GENERICNAME AND MANUFACTURER, 2012Table 23 : CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME,TYPE AND MANUFACTURER, 2012Table 24 : MEDICATIONS USED TO TREAT GENITAL WARTS BY BRAND NAME, GENERICNAME AND MANUFACTURERTable 25 : CURRENT PRODUCTS USED TO DIAGNOSE GONORRHEATable 26 : CURRENT MEDICATIONS USED TO TREAT GONORRHEATable 27 : CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BYBRAND NAME, TYPE AND MANUFACTURER, 2012Table 28 : VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2012Table 29 : CDC CLASSIFICATION OF HIV INFECTIONTable 30 : CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HIV/AIDS BY BRANDNAME, TYPE AND MANUFACTURER, 2012Table 31 : HIV LIFE CYCLETable 32 : FDA-APPROVED GENERIC DRUGS FOR TREATMENT OF HIV, 2012Table 33 : CURRENTLY APPROVED PHARMACEUTICAL PRODUCTS FOR TREATMENT OFHIV/AIDS BY BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012Table 34 : HIV TREATMENT MARKET, BY MANUFACTURERTable 35 : CURRENT TREATMENTS FOR PEDICULOSIS PUBIS BRAND NAME, GENERICNAME AND MANUFACTURERTable 36 : CURRENT TREATMENTS FOR PID BRAND NAME, GENERIC NAME ANDMANUFACTURERTable 37 : CURRENT TREATMENTS FOR SCABIES BRAND NAME, GENERIC NAME ANDMANUFACTURERTable 38 : STAGES OF SYPHILISTable 39 : CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY BRANDNAME, TYPE AND MANUFACTURER, 2012Table 40 : DIAGNOSTIC ASSAYS FOR DETECTION OF TRICHOMONAS WITH BRAND NAME,TYPE AND MANUFACTURERTable 41 : CURRENT MEDICATIONS FOR THE TREATMENT OF TRICHOMONASTable 42 : PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECTSTDS BY DISEASE, THROUGH 2017Table 43 : PROJECTED GLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS BY REGION,THROUGH 2017Table 44 : PROJECTED GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS,THROUGH 2017Table 45 : PROJECTED GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS BYREGION, THROUGH 2017Table 46 : PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE AMERICAS,THROUGH 2017Table 47 : PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE
  7. 7. AMERICAS, BY DISEASE, THROUGH 2017Table 48 : ESTIMATED ANNUAL NUMBER OF PREGNANT WOMEN WITH AN STD IN THEU.S.Table 49 : ANNUAL INCIDENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., 2010Table 50 : PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE EMRA,THROUGH 2017Table 51 : PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE EMRABY DISEASE, THROUGH 2017Table 52 : PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE,THROUGH 2017Table 53 : PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN ASIA BYDISEASE, THROUGH 2017Table 54 : PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.Table 55 : SEXUALLY TRANSMITTED DISEASE PHARMACEUTICAL PRODUCT PIPELINE,2012Table 56 : STD PHARMACEUTICAL PATENTS BY PATENT NUMBER, DISEASE, COMPANY,PRODUCT DESCRIPTION, AND APPROVAL DATE FEBRUARY 2006–OCTOBER 2012Table 57 : STD DIAGNOSTIC PATENTS BY PATENT NUMBER, DISEASE, COMPANY,PRODUCT DESCRIPTION AND APPROVAL DATE MARCH 2005-OCTOBER 2012Table 58 : STD PHARMACEUTICAL PRODUCT PATENTS, BY MAJOR COMPANY JANUARY2005–OCTOBER 2012Table 59 : STD DIAGNOSIS AND TREATMENT PATENTS BY COUNTRY JANUARY2005–OCTOBER 2012Table 60 : PATENTS ISSUED FOR DIAGNOSIS AND TREATMENT OF STDS BY DISEASE,MARCH 2005–OCTOBER 2012Table 61 : ABBOTT PHARMACEUTICAL PRODUCTSTable 62 : ABBOTT DIAGNOSTIC PRODUCTSTable 63 : ALERE DIAGNOSTIC PRODUCTSTable 64 : ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTSTable 65 : ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTSTable 66 : BAYER PHARMACEUTICAL PRODUCTSTable 67 : BECTON DICKINSON DIAGNOSTIC PRODUCTSTable 68 : BIOMERIEUX DIAGNOSTIC PRODUCTSTable 69 : BIO-RAD LABORATORIES DIAGNOSTIC PRODUCTSTable 70 : BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTSTable 71 : BRISTOL-MEYERS SQUIBB PHARMACEUTICAL PRODUCTSTable 72 : CREATIVE DIAGNOSTICS DIAGNOSTIC PRODUCTSTable 73 : DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTSTable 74 : DIASORIN DIAGNOSTIC PRODUCTSTable 75 : ENZO BIOCHEM DIAGNOSTIC PRODUCTSTable 76 : FIRST DIAGNOSTIC DIAGNOSTIC PRODUCTSTable 77 : GILEAD SCIENCES PHARMACEUTICAL PRODUCTS
  8. 8. Table 78 : GLAXOSMITHKLINE PHARMACEUTICAL PRODUCTSTable 79 : HOLOGIC/GEN-PROBE DIAGNOSTIC PRODUCTSTable 80 : HOME ACCESS HEALTH DIAGNOSTIC PRODUCTSTable 81 : IMMUNOSTICS DIAGNOSTIC PRODUCTSTable 82 : IND DIAGNOSTIC, INC DIAGNOSTIC PRODUCTSTable 83 : JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTSTable 84 : MERCK PHARMACEUTICAL PRODUCTSTable 85 : MERIDIAN BIOSCIENCE DIAGNOSTIC PRODUCTSTable 86 : NOVARTIS DIAGNOSTIC PRODUCTSTable 87 : ORASURE TECHNOLOGIES DIAGNOSTIC PRODUCTSTable 88 : ORTHO CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTSTable 89 : PFIZER PHARMACEUTICAL PRODUCTSTable 90 : PRINCETON BIOMEDITECH DIAGNOSTIC PRODUCTSTable 91 : QIAGEN DIAGNOSTIC PRODUCTSTable 92 : QUIDEL DIAGNOSTIC PRODUCTSTable 93 : REMEL/THERMOFISHER SCIENTIFIC DIAGNOSTIC PRODUCTSTable 94 : ROCHE PHARMACEUTICAL PRODUCTSTable 95 : ROCHE DIAGNOSTIC PRODUCTSTable 96 : SEKISUI DIAGNOSTICS DIAGNOSTIC PRODUCTSTable 97 : SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTSTable 98 : STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTSTable 99 : TRINITY BIOTECH DIAGNOSTIC PRODUCTSTable 100 : VERTEX PHARMACEUTICALS PHARMACEUTICAL PRODUCTSTable 101 : VIIV HEALTHCARE PHARMACEUTICAL PRODUCTSLIST OF FIGURESSummary Figure : GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLYTRANSMITTED DISEASES, 2011 AND 2017Figure 1 : TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET ANDTHEIR MARKET SHARE, 2011Figure 2 : MARKET SHARE OF LEADING COMPANIES IN THE HIV/AIDS TREATMENTMARKET, 2011Figure 3 : 2011 MARKET SHARE FOR BRANDED HIV DRUGS, BY MANUFACTURERFigure 4 : MARKET SHARE FOR TYPES OF TESTS USED TO DIAGNOSE STDS, 2012Figure 5 : GLOBAL STD DIAGNOSTIC MARKET, BY REGION 2012 AND 2017Figure 6 : GLOBAL STD PHARMACEUTICAL MARKET BY REGION 2012 AND 2017Figure 7 : MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE AMERICAS BY DISEASE,2012 AND 2017Figure 8 : MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE AMERICAS BYDISEASE, 2012 AND 2017Figure 9 : MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE EMRA BY DISEASE, 2012AND 2017Figure 10 : MARKET FOR STD TREATMENT PRODUCTS IN THE EMRA BY DISEASE, 2012
  9. 9. AND 2017Figure 11 : MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE, 2012 AND2017Figure 12 : MARKET FOR STD TREATMENT PRODUCTS IN ASIA BY DISEASE, 2012 AND2017Contact: sales@reportsandreports.com for more information.

×